Allogene Therapeutics Modifies ALPHA3 Trial Design Following Patient Death, Adopts Standard Lymphodepletion Protocol
Key Insights
Allogene Therapeutics has discontinued the FC plus ALLO-647 lymphodepletion arm in its ALPHA3 trial after a patient death from hepatic failure attributed to disseminated adenovirus infection.
The company will proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma.
This strategic shift eliminates ALLO-647 from all current trials and accelerates focus on the company's next-generation Dagger Platform Technology for future CAR-T development.
Allogene Therapeutics has made a significant protocol modification to its pivotal ALPHA3 trial following a patient death attributed to its experimental lymphodepletion regimen. The clinical-stage biotechnology company announced it will discontinue the arm testing fludarabine and cyclophosphamide plus ALLO-647 (FCA) and proceed exclusively with standard fludarabine and cyclophosphamide (FC) lymphodepletion for its allogeneic CAR-T therapy cemacabtagene ansegedleucel (cema-cel).
Fatal Adverse Event Prompts Protocol Change
The decision was made in conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, following consultation with the FDA after a Grade 5 adverse event occurred in the FC plus ALLO-647 arm. The patient died on Day 54 post-infusion from hepatic failure, believed to have resulted from disseminated adenovirus infection in the setting of immune suppression caused by ALLO-647, an anti-CD52 (search) monoclonal antibody.
The event was deemed unrelated to cema-cel itself. According to the company, severe viral infections have been rare across Allogene's clinical trials but when present have been attributed to immunosuppression due in part to ALLO-647. Notably, there have been no cases of adenoviral infection or hepatic failure in any participant treated with FC lymphodepletion across Allogene's trials.
"The loss of a patient is always deeply saddening, and we extend our heartfelt condolences to the patient's family," said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene. "This event, which prompted an early review of the trial data, compelled us to make a decisive choice - one that may ultimately help bring this potentially life-saving therapy to patients more quickly."
Strategic Shift in Clinical Development
The adoption of standard FC lymphodepletion represents a key strategic pivot for Allogene. The company indicated that no trials open to enrollment or pipeline programs now include ALLO-647. Instead, Allogene is advancing its next-generation AlloCAR T product candidates using the proprietary Dagger Platform Technology, which is designed to minimize or potentially eliminate the need for standard lymphodepletion.
This approach is being showcased in the ALLO-316 TRAVERSE trial for advanced renal cell carcinoma and the ALLO-329 RESOLUTION trial for autoimmune diseases, both of which leverage the Dagger Technology to reduce reliance on traditional lymphodepletion strategies.
Modified Trial Design and Timeline
The amended ALPHA3 trial now proceeds as a randomized study with two arms, comparing cema-cel after standard FC lymphodepletion to observation, the current standard of care. The statistical design of the trial and prespecified study conduct remain unchanged. An unplanned review of safety and biomarker data with standard FC and cema-cel indicated an encouraging MRD conversion rate and safety profile.
The next milestone will be the futility analysis comparing MRD conversion, expected to occur in the first half of 2026 as originally planned. To date, over 50 clinical sites are activated across the United States and Canada, including community cancer centers and major academic institutions.
Addressing Unmet Need in Large B-Cell Lymphoma
The ALPHA3 study targets a significant unmet medical need in large B-cell lymphoma (LBCL), with over 60,000 patients expected to be treated annually in the US, EU, and UK. While first-line R-CHOP (search) or other chemoimmunotherapy is effective for most patients, approximately 30% who initially respond will relapse and require subsequent treatment.
The current standard of care after first-line treatment has been to "watch and wait" to see if the disease relapses. The ALPHA3 study positions cema-cel as a one-time, "off-the-shelf" treatment that can be administered immediately upon discovery of minimal residual disease (MRD) following six cycles of R-CHOP (search) or other chemoimmunotherapy, potentially becoming the standard "7th cycle" of frontline treatment.
Chang emphasized that the ability to administer cema-cel following standard FC lymphodepletion in an outpatient setting will simplify study treatment and has the potential to accelerate trial enrollment and streamline regulatory review, ultimately transforming care for patients.